JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Sustainable Practices in Pharmaceutical Waste Management

J S Varshini K*, Usha Rani E

Department of Pharmaceutics, Pydah College of Pharmacy, Patavala, Andhra Pradesh, India

Publication history: Received on 21st January 2026; Revised on 1st March 2026; Accepted on 2nd March 2026

Article DOI: 10.69613/s71xx842

Abstract: Pharmaceutical waste, comprising expired, unused, and contaminated medicinal products, represents a critical challenge to public health and environmental integrity. Global escalation in pharmaceutical consumption has led to significant accumulation of both hazardous and non-hazardous residues, originating from diverse sources such as clinical facilities, industrial units, and residential households. Improper disposal mechanisms facilitate the entry of active pharmaceutical ingredients into aquatic ecosystems, contributing to ecotoxicity and the proliferation of antimicrobial resistance. Effective management necessitates a multi-tiered approach involving rigorous segregation, standardized color-coding, and specialized treatment modalities including high-temperature incineration, autoclaving, and chemical disinfection. Regulatory oversight by agencies such as the Environmental Protection Agency and the Drug Enforcement Administration ensures compliance with biosafety and environmental standards. The pharmacist occupies a pivotal position in this ecosystem, facilitating medication reconciliation, patient education, and the implementation of take-back programs to minimize waste at the source. Resource recovery and waste immobilization techniques like encapsulation and inertization provide viable pathways for mitigating the environmental footprint of highly potent active pharmaceutical ingredients. Shifting toward sustainable waste life cycles through inventory optimization and policy-driven interventions remains essential for safeguarding ecological health and ensuring regulatory adherence in modern healthcare systems.

Keywords: Pharmaceutical Waste; Hazardous Drugs; Pharmacist Role; Waste Treatment; Environmental Protection.

1. Introduction

Pharmaceutical waste is a highly heterogeneous category of medicinal products that are no longer suitable for their intended therapeutic applications. This classification is not limited merely to chemical substances but extends to a broad range of materials, including expired formulations, unused or damaged drugs, sub-standard products, and contaminated delivery systems. It encompasses pharmaceutical primary and secondary packaging that may be partially filled or entirely empty but remains contaminated with trace active residues [1]. The definition of such waste is critical because it identifies the point at which a therapeutic asset becomes an environmental liability. The generation of these residues has accelerated across multiple sectors as healthcare systems expand to meet the demands of an aging population and increasing chronic disease prevalence, including hospital pharmacies, specialized clinics, pharmaceutical manufacturing units, and residential settings.

The global rise in drug consumption has precipitated a proportional surge in waste volume, creating an unprecedented logistics and safety burden. Empirical research conducted within tertiary care hospital settings reveals that daily waste generation can exceed 150 kg, with a significant proportion of this mass attributed to intravenous serums, glass vials, and ampoules [2]. Such high volumes in clinical environments highlight the need for robust institutional protocols to handle the physical mass and chemical potency of discarded materials. While industrial and clinical sources are often the focus of regulatory attention, the contribution of household pharmaceutical disposal often involving the disposal of unused medications via municipal trash or domestic sewage remains a significant but poorly quantified factor in the overall waste stream.

The absence of systematic and harmonized disposal protocols in many global regions, particularly within developing economies, exacerbates the risk of large-scale environmental contamination. In many jurisdictions, pharmaceutical residues are still treated as general municipal waste due to a lack of specialized infrastructure or insufficient awareness of their unique chemical risks [3]. This regulatory vacuum leads to the direct leaching of active ingredients into soil and groundwater, where they can persist for extended periods. The challenge is further complicated by the diversity of drug classes involved, ranging from common analgesics to highly potent hormonal therapies and oncology drugs, each requiring distinct neutralization pathways to prevent ecological disruption.

* Corresponding author: J S Varshini K

Active pharmaceutical ingredients (APIs) released into the environment pose persistent threats to biodiversity, ecosystem services, and human health. The infiltration of these bioactive compounds into aquatic systems is particularly concerning as they can affect the endocrine systems of aquatic species and enter the human food chain through bioaccumulation. One of the most severe consequences of improper disposal is the burgeoning crisis of antimicrobial resistance (AMR). Sub-lethal concentrations of antibiotics present in wastewater create selective pressure that facilitates the survival and proliferation of resistant microbial strains [4]. This phenomenon threatens to reverse decades of progress in infectious disease management, making standard treatments ineffective and increasing the mortality rates associated with common infections.

Consequently, establishing standardized and scientifically grounded protocols for the identification, segregation, and treatment of these materials is a priority for healthcare administrators, environmental scientists, and policymakers alike [5]. The complexity of modern pharmacopeias necessitates a move away from "one-size-fits-all" disposal methods toward a more nuanced, risk-based approach. Effective management requires a granular understanding of the chemical stability and toxicity of various drug classes. Organizations can ensure that hazardous substances are diverted from general waste streams and subjected to appropriate high-level treatment by implementing rigorous tracking systems from the point of procurement to the final stage of disposal.

Current management strategies prioritize the mitigation of ecological harm while promoting resource efficiency and regulatory compliance through collaborative efforts between clinical practitioners, waste engineers, and environmental agencies [6]. This integrated approach moves beyond simple disposal, looking at the entire lifecycle of the drug to identify opportunities for waste reduction and resource recovery. It is possible to develop sustainable practices that balance the necessity of high-quality medical care with the imperative of environmental preservation by fostering a culture of environmental stewardship within the pharmaceutical industry and healthcare facilities. This necessitates not only technological innovation in waste treatment but also a fundamental shift in how pharmaceutical products are dispensed, managed, and perceived throughout their utility.

2. Characterization and Classification of Pharmaceutical Waste

The initial phase of any waste management program involves the precise identification and categorization of the materials involved. Pharmaceutical waste is fundamentally divided based on its toxicological profile and the specific risks it poses to handlers and the ecosystem [7].

2.1. Hazardous Pharmaceutical Residues

Hazardous waste represents the most significant threat within the pharmaceutical stream. This category includes highly potent active pharmaceutical ingredients (HPAPIs), cytotoxic agents used in oncology, and substances that exhibit characteristics of toxicity, corrosivity, or reactivity [8].

Table 1. Comparison of Hazardous vs. Non-Hazardous Pharmaceutical Waste

Feature	Hazardous Pharmaceutical Waste	Non-Hazardous Pharmaceutical Waste
Characteristics	Infectious, toxic, genotoxic, or reactive substances.	General clinical residues without immediate toxic profile.
Examples	Cytotoxic drugs, HPAPIs, heavy metal-containing reagents, solvents.	Expired vitamins, saline solutions, non-contaminated packaging, paper.
Regulatory Guidelines	Biomedical Waste Management (BMW) Rules; EPA RCRA guidelines.	Municipal Solid Waste Management Rules.
Environmental Risk	Bioaccumulation, groundwater toxicity, endocrine disruption.	Landfill volume accumulation, minor chemical leaching.
Handling	Specialized containment and PPE; strict track-and-trace.	Standard segregation post-debranding/unpackaging.

2.1.1. Potent and Cytotoxic Agents

Substances such as chemotherapy drugs require stringent containment because of their mutagenic and teratogenic potential. These materials demand specialized handling to prevent accidental exposure to healthcare personnel and to ensure that no residues enter municipal waste streams where they could cause irreversible damage to soil microbiota [9].

2.1.2. Chemically Reactive and Toxic Waste

Beyond therapeutic agents, the hazardous category includes solvents, heavy metals, and chemicals used in laboratory diagnostics. These components are regulated under specific biomedical waste management frameworks that mandate treatment before final disposal to neutralize their hazardous properties [10].

2.2. Non-Hazardous Waste Streams

Non-hazardous pharmaceutical waste consists of substances that do not pose an immediate biological or chemical threat but still require controlled disposal to prevent misuse [11].

2.2.1. General Medications

Common over-the-counter medications and non-toxic prescription drugs fall into this category. Although they lack the extreme toxicity of HPAPIs, their cumulative presence in landfills can still lead to the leaching of chemical components into the environment if not managed appropriately [12].

2.2.2. Contaminated Packaging and Containers

Containers that have held pharmaceutical products are often classified as waste. Even if empty, these items may retain trace amounts of medications, necessitating specialized disposal to avoid contamination of recycled materials such as paper or plastic [13].



Figure 1. Operational logic for the segregation of pharmaceutical and clinical waste based on hazard potential and physical characteristics

3. Socio-Environmental Impacts and Management Rationale

The justification for rigorous waste management extends beyond simple cleanliness, involving complex intersections of public safety, legal accountability, and economic efficiency.

3.1. Advantages of Systematic Management

Implementing a structured approach to waste disposal offers multi-faceted benefits that protect both the community and the institution.

3.1.1. Public Health and Environmental Integrity

The primary benefit of effective management is the prevention of accidental poisoning and the reduction of medicinal residues in the food chain. Healthcare systems safeguard the population from ineffective or harmful treatments by ensuring that expired medications are not diverted to unauthorized markets or improperly discarded [14].

3.1.2. Regulatory Compliance and Ethical Responsibility

Adherence to strict disposal guidelines allows healthcare facilities and pharmaceutical manufacturers to maintain legal standing and display corporate social responsibility. Compliance with state and federal regulations prevents the heavy penalties associated with environmental violations and maintains the trust of the public [15].

3.1.3. Economic and Resource Efficiency

Effective management often leads to long-term cost savings. Facilities can lower their disposal expenditures by optimizing inventory and reducing the volume of waste generated. Certain non-hazardous materials may be eligible for resource recovery, where they are repurposed into useful industrial components, thereby reducing the overall ecological footprint of the facility [16, 17].

4. The Role of Pharmacists in Waste Mitigation

Pharmacists hold a strategic position within the medication life cycle, serving as the final intermediary between pharmaceutical products and the end-user. Their clinical expertise is essential for implementing interventions that minimize waste and ensure the safe disposal of medicinal residues [18].

4.1. Prescription Management and Pharmaceutical Care

Optimizing therapeutic regimens through precise prescription management directly reduces the volume of unused medications. Pharmacists facilitate pharmaceutical care by educating patients on medication adherence, thereby preventing the accumulation of unused drugs resulting from non-compliance. They ensure that patients receive the most effective treatment by monitoring drug interactions and adverse reactions, minimizing the need for therapeutic switches that often lead to discarded stock [19].

4.2. Guidance on Appropriate Disposal

As accessible healthcare providers, pharmacists provide vital information to the public regarding the environmental risks associated with improper disposal. This includes discouraging the flushing of medications down domestic sewers and promoting the use of designated collection bins. Community-based take-back programs, often spearheaded by pharmacy departments, provide a secure route for the return of expired controlled substances, preventing potential abuse and environmental contamination [20].

4.3. Leadership in Institutional Waste Policies

Within hospital settings, pharmacists contribute to the development of formulary management and inventory controls. Their involvement in "just-in-time" procurement strategies and the monitoring of emergency syringe dating helps align supply with actual clinical demand. These initiatives are foundational to building a facility-wide mechanism for environmental management [21].



Figure 2. Hierarchy of Methods for pharmaceutical waste management, prioritizing source reduction and inventory management over end-of-pipe treatment.

5. Methods for Waste Treatment and Final Disposal

Selecting an appropriate treatment modality depends on the chemical nature of the waste and the local regulatory environment. Modern waste management employs several technological interventions to neutralize biological and chemical hazards.

5.1. Incineration

Incineration is a high-temperature dry oxidation process that reduces the volume of solid waste by 70% to 80% while converting organic matter into heat, gas, and ash. This method is particularly effective for hazardous materials, including cytotoxic drugs and contaminated sharps. While efficient for large-scale operations, the process must be carefully monitored to prevent the release of toxic gaseous pollutants such as dioxins. Ash residues from this process are subsequently transferred to secured landfills [22].

5.2. Autoclaving

Autoclaving utilizes saturated steam under high pressure to eliminate microbial pathogens in biomedical waste. This technique is highly effective for disinfecting materials like bandages and gowns, which can then be safely discarded in municipal landfills. However, it is not suitable for chemical or pharmaceutical waste that requires chemical neutralization or high-temperature degradation [23].



Figure 3. Lifecycle of pharmaceutical waste from the point of clinical generation to final environmental containment.

5.3. Electromagnetic Disinfection: Microwave Technology

Microwave treatment employs conduction and electromagnetic fields to destroy infectious components within waste streams. This method is often preferred for its lower energy consumption and operational simplicity compared to large-scale incinerators. Its primary limitation lies in its inability to process large metal components or anatomical waste [11, 24].

Table 2. Evaluation of Common Treatment and Disposal Methods

Method	Mechanism of Action	Primary Application	Advantages	Limitations
Incineration	High-temperature oxidation (800°C–1200°C).	Cytotoxics, sharps, hazardous solids.	Significant volume reduction (80%); complete destruction.	Emission of dioxins/furans; high operational cost.
Autoclaving	Saturated steam sterilization under pressure.	Contaminated plastics, bandages, microbial cultures.	Low cost; high biological safety; chemical-free.	Ineffective for chemical/cytotoxic residues; high energy use.
Microwave	Electromagnetic conduction/heating.	Infectious clinical waste; small metal components.	Rapid processing; low energy consumption; no toxic emissions.	Not suitable for anatomical waste or large metal items.
Chemical Disinfection	Chemical inactivation (Phenols/Aldehydes).	Liquid waste (blood, urine, lab effluents).	Immediate pathogen neutralization.	Hazardous byproducts; environmental toxicity of reagents.
Encapsulation	Immobilization in cement/lime matrices.	Solid pills, semi-solids, heavy metal residues.	Prevents leaching; low technology requirement.	Does not destroy chemicals; occupies landfill space.

5.4. Chemical Disinfection and Immobilization

Liquid wastes, such as laboratory reagents or biological fluids, are often neutralized using chemical disinfectants like phenols or strong antioxidants. For solid pharmaceutical residues, immobilization techniques such as encapsulation and inertization are employed. Encapsulation involves sealing waste in steel or plastic drums with a media of cement and lime, whereas inertization involves grinding medications into a paste mixed with binding agents before landfilling [25].

5.5. Advanced Landfilling and Deep Burial

In rural or low-resource areas, deep burial in prepared trenches provides a practical solution for biological waste. In more developed regions, secure landfills utilize clay or plastic linings to prevent leachate from contaminating groundwater. Modern landfills also incorporate perforated pipe systems to extract methane and carbon dioxide for potential energy generation [26].

6. Systematic Segregation and Color-Coding

Standardized segregation is critical to preventing cross-contamination between hazardous and non-hazardous waste streams. Recent guidelines emphasize color-coded containers to facilitate rapid and accurate sorting by healthcare personnel.

6.1. Infectious and Soiled Waste (Red Containers)

Materials such as soiled gloves, catheters, and intravenous tubing that have been in contact with biological fluids are disposed of in red bags. These items typically undergo thermal treatment or deep burial post-collection [27].

6.2. Biohazardous and Anatomical Waste (Yellow Containers)

Yellow bags are reserved for highly infectious materials, including dressings, blood bags, and anatomical parts. This waste stream is prioritized for high-temperature incineration to ensure complete biological neutralization [28].

6.3. Glassware and Sharps (Blue and White PPCs)

Glass vials and ampules are collected in cardboard boxes marked with blue identifiers. For needles, scalpels, and other sharp instruments, white Puncture-Proof Containers (PPCs) are mandatory to prevent needle-stick injuries among sanitation workers [29].

6.4. General Municipal Waste (Black Containers)

Non-biomedical residues, including food waste, packaging, and stationery, are collected in black bags. This waste stream is handled through standard municipal collection systems, provided it has been properly segregated from hazardous materials [15].

Table 3. Standardized Color-Coding for Segregation of Bio-Medical Waste

Container Color	Target Waste Category	Specific Examples	Preferred Treatment Method
Yellow Bag	Highly infectious/Anatomical waste.	Dressings, blood bags, body parts, biohazardous liners.	Incineration or deep burial.
Red Bag	Contaminated recyclables.	Soiled gloves, IV tubes, catheters, syringes (without needles).	Autoclaving followed by shredding.
Blue Box	Glassware and metallic implants.	Vials, ampules, glass slides.	Disinfection and recycling.
White (PPC)	Sharps and metallic waste.	Needles, scalpels, blades, lancets.	Autoclaving and metal recovery.
Black Bag	Non-biomedical/General waste.	Food scraps, stationery, office paper, outer packaging.	Municipal landfilling.

7. Opportunities for Waste Minimization

While the hazardous nature of many medicinal compounds is inherent to their therapeutic efficacy, systemic interventions can significantly reduce the volume of waste generated. Minimization strategies focus on procurement, clinical administration, and inventory oversight to alleviate environmental and compliance burdens.

7.1. Procurement and Inventory Optimization

Effective waste reduction begins with a critical analysis of the pharmaceutical lifecycle during the purchasing phase. Implementing a samples policy and evaluating container sizes in relation to actual usage patterns prevents the accumulation of bulk quantities that may expire before use. Healthcare facilities can minimize the risk of updates and stock redundancies by utilizing "just-in-time" inventory controls [30].

7.2. Clinical Administration and Practice Modifications

In clinical settings, specific practices can be modified to reduce pharmaceutical residues. For instance, maximizing the utility of opened chemotherapy vials and using saline solutions to prime and flush intravenous lines minimizes the loss of active ingredients. The use of patient-specific oral syringes instead of prepackaged unit-dose liquids allows for more precise dosing and reduces the volume of primary packaging waste. Rigorous monitoring of emergency syringe dating ensures that medications are rotated effectively before reaching their expiration [31, 32].

7.3. Guidelines for Institutional Policy Execution

Sustainable waste management requires the formalization of policies that describe the organization's method for determining hazardous waste status. These policies should include labeling protocols to facilitate the segregation of unregulated medications and the establishment of satellite accumulation areas. Frequent program evaluations and personnel training are essential to ensuring that minimization strategies are integrated into the facility-wide environmental mechanism [33].

Table 4. Inventory and Clinical Strategies for Waste Minimization

Strategy Level	Intervention Technique	Objective
Procurement	"Just-in-Time" (JIT) Inventory	Reduces overstocking and expiration risks.
Clinical Practice	Chemotherapy Vial Optimization	Minimizes loss of high-potency active ingredients.
Patient Care	Medication Adherence Education	Prevents unused stock resulting from treatment failure.
Administration	Patient-Specific Unit Dosing	Eliminates waste from bulk liquid containers.
Facility-Wide	Emergency Drug Rotation	Ensures medications are used before their dating expiration.

8. Administrative Oversight and Governance

Pharmaceutical waste management is governed by a complex network of agencies that ensure public safety and environmental protection. Compliance with these frameworks is mandatory for clinical, industrial, and retail pharmaceutical entities.

8.1. Federal Environmental and Drug Oversight

The Environmental Protection Agency (EPA) provides the foundational standards for the management of hazardous waste under the Resource Conservation and Recovery Act. Simultaneously, the Drug Enforcement Administration (DEA) oversees the disposal of controlled substances to prevent diversion and abuse. These agencies collaborate to ensure that pharmaceutical residues do not compromise air or water quality [34, 35].

8.2. Workplace Safety and Transportation Regulations

The Occupational Safety and Health Administration (OSHA) sets standards to protect healthcare workers from exposure to hazardous drugs during handling and disposal. For waste that must be transported to off-site treatment facilities, the Department of Transportation (DOT) regulates the containment and labeling of pharmaceutical materials to prevent accidental releases during transit [36, 37].

Table 5. Regulatory Bodies and Their Primary Role in Waste Management

Regulatory Body	Acronym	Primary Responsibility in Waste Management
Environmental Protection Agency	EPA	RCRA enforcement; hazardous waste classification; water protection.
Drug Enforcement Administration	DEA	Oversight of controlled substance disposal and diversion prevention.
Occupational Safety & Health Admin	OSHA	Protection of personnel handling hazardous/infectious materials.
Department of Transportation	DOT	Regulation of off-site transport, packaging, and labeling.
State Pharmacy Boards	SPB	Licensing of take-back programs and retail disposal compliance.

8.3. State and Local Governance

In addition to federal mandates, state environmental agencies and pharmacy boards provide localized oversight, often implementing more stringent requirements for waste segregation and reporting. Publicly Owned Treatment Works (POTW) also play a role by monitoring the discharge of pharmaceutical-laden wastewater into municipal sewer systems [38, 39, 40].

9. Conclusion

Effective pharmaceutical waste management demands integrated approaches segregation, advanced treatments, pharmacist involvement, and regulatory compliance to curb ecological harm and public health risks. Efforts should prioritize awareness campaigns, innovative bioremediation, and policy enforcement for sustainable practices, ensuring a healthier planet. Shifting toward sustainable waste life cycles through inventory optimization and policy-driven interventions remains essential for safeguarding ecological health and ensuring regulatory adherence in modern healthcare systems.

References

[1] Adragos Pharma. Pharmaceutical waste management: steps for compliance and sustainability. 2024.

[2] Kolte SS, Munjaji K, Ameen M, Ahmad J. Pharmaceutical waste management and its impact on environmental. International Journal of Research in Pharmacy and Pharmaceutical Sciences. 2023;8(3):48-52.

[3] Akter N. Medical waste management: a review. Environmental Engineering Program, Asian Institute of Technology, Thailand. 2000:1-25.

[4] Shukla T, Bajaj R, Khanna S, Pandey SP, Dubey R, Upmanyu N. Role of pharmacist in pharmaceutical waste management. World Journal of Environmental Biosciences. 2017;6(2):1-13.

[5] Sreekanth K, Gupta NV, Raghunandan HV, Kashyap UN. A review on managing of pharmaceutical waste in industry. International Journal of PharmTech Research. 2014;6(3):899-907.

[6] Verma R. Pharmaceutical waste or scrap management. 2011.

[7] Sanwal S. Which type of biomedical waste is hazardous and non-hazardous. Mywaste Articles. 2024.

[8] Kumar P. Biomedical waste management rules, 2016.

[9] DCCEEW. Exporting, importing or transiting hazardous waste. 2022.

[10] Shinde AR, Patil AP, Patil TM, Vakhariya RR, Magdum CS. Pharmaceutical waste management: significant for health of nature and future. International Journal of Pharmaceutical Sciences Review and Research. 2020;65(2):68-74.

[11] Bhosale M, Mankar S, Malvade P, Chavan S. Overall review on current scenario in waste management system. Asian Journal of Management. 2022;13(3).

[12] Kadam A, Patil S, Patil S, Tumkur A. Pharmaceutical waste management an overview. Indian Journal of Pharmaceutical Practice. 2016;9(1):2-8.

[13] Burke M, Smith C. Waste watch: a model for managing discarded pharmaceuticals. Health Facilities Management. 2006;19(3):43-47.

[14] Smith CA. Rationale for inclusion of criteria for proper disposal of monograph pharmaceutical preparations based on the Resource Conservation and Recovery Act. Pharmacopeial Forum. 1999;25(3):8309-8312.

[15] Sharma N, et al. Pharmaceutical waste management: a challenge to make environment ecofriendly. 2020.

[16] Guidelines for management of healthcare waste as per Biomedical Waste Management Rules, 2016.

[17] Sengodan VC. Segregation of biomedical waste in an South Indian tertiary care hospital. Journal of Natural Science, Biology and Medicine. 2014;5(2):378-382.

[18] Celitron. Biomedical waste management colour coding for beginners. celitron.com. 2019.

[19] Mankar SD, Kawade M, Parjane S. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021;13(3):247-252.

[20] Stanek LW, Cascio WE, Barzyk TM, et al. Environmental public health research at the US Environmental Protection Agency. Journal of Exposure Science & Environmental Epidemiology. 2025;35(4):539-547.

[21] Wood L, Scott TA. Transportation agencies as consumers and producers of science. Transport Policy. 2022;128:153–165.

[22] Van Puyvelde D. Drug Enforcement Administration (DEA). Encyclopedia of Big Data. 2022:414–418.

[23] Cuming RG, Rocco TS, McEachern AG. Improving compliance with occupational safety and health administration standards. AORN Journal. 2008;87(2):347-360.

[24] Devarhubli G, Shrivastava A. The advancement of environmental procedural rights in India: an analysis of issues, problems and prospects. Cogent Social Sciences. 2024;10(1).

[25] Milenkovich N. State boards of pharmacy wield control and power. 2020;86.

[26] Butson N. Evaluation of a publicly owned treatment works to accept new loading from an existing industrial user. Access Water, Water Environment Federation. 2023.

[27] World Health Organization. Guidelines for safe disposal of unwanted pharmaceuticals in and after emergencies. Geneva: WHO; 1999.

[28] Al-Qarni H, et al. Environmental pollution and pharmaceutical waste: A review of management and disposal practices. Journal of Environmental Science and Health. 2016;51(12):1-14.

[29] Glassmeyer ST, et al. Disposal of unwanted medicines: A review of collection programs and environmental impacts. Environmental Pollution. 2009;157(11):3151-3159.

[30] Daughton G. Pharmaceuticals and the environment: stewardship and management. ACS Symposium Series. 2014;1164:1-38.

[31] Becker C, et al. Impact of hospital pharmaceutical waste on the environment: a review. Environmental Science and Pollution Research. 2020;27:26047–26061.

[32] Bound JP, Voulvoulis N. Household disposal of unused and expired pharmaceuticals. Environmental Health Perspectives. 2005;113(12):1705-1711.

[33] Smith CA. Managing pharmaceutical waste: What pharmacists need to know. Journal of the American Pharmacists Association. 2002;42(5):S1-S4.

[34] US Environmental Protection Agency (EPA). Resource Conservation and Recovery Act (RCRA) Regulations. 40 CFR Parts 260-273.

[35] Drug Enforcement Administration (DEA). Secure and Responsible Drug Disposal Act of 2010. Public Law 111–273.

[36] Occupational Safety and Health Administration (OSHA). Controlling Occupational Exposure to Hazardous Drugs. TED 01-00-015.

[37] US Department of Transportation (DOT). Hazardous Materials Regulations (HMR). 49 CFR Parts 171-180.

[38] Tong AY, Peake BM, Braund R. Disposal of unused medicines: a review. International Journal of Environmental Research and Public Health. 2011;8(12):4563-4575.

[39] Lubick N. Drugs in the environment: do pharmaceutical take-back programs make a difference? Environmental Health Perspectives. 2010;118(5):A210-A214.

[40] Heberer T. Tracking of pharmaceutical residues in the aquatic environment. Journal of Hydrology. 2002;266(3-4):175-189.